When you read about a promising new supplement or health intervention, you might wonder: how do scientists know it actually works? The journey from laboratory discovery to your medicine cabinet involves multiple stages of testing, and understanding the difference between animal vs human study research is crucial for making informed decisions about your health.
Whether you’re exploring options for muscle health, digestive wellness, or healthy aging, knowing how scientific evidence is gathered can help you evaluate health claims more critically. Let’s break down what separates preclinical animal research from human clinical trials and why both play important roles in developing safe, effective health solutions.
What Are Animal Studies?
Animal studies, also called preclinical research, are experiments conducted in laboratory animals before any testing occurs in humans. These studies typically use mice, rats, rabbits, or sometimes larger animals like dogs or primates to evaluate whether a new compound might be safe and effective.
The primary goals of animal studies include determining safe starting doses, identifying potential side effects, and understanding how a substance is absorbed, distributed, metabolized, and eliminated by the body. Before the FDA allows human testing to begin, researchers must demonstrate that a potential treatment doesn’t cause serious harm in at least two mammalian species—typically one rodent and one non-rodent.
Animal models allow scientists to study biological mechanisms in controlled conditions. For instance, researchers can examine specific organs, measure molecular changes, and observe effects over an animal’s entire lifespan in ways that would be impossible or unethical in humans. When studying muscle health interventions, animal studies might measure muscle fiber size, grip strength, and exercise endurance in mice receiving a novel compound.
What Are Clinical Trials?
Clinical trials are research studies conducted in human volunteers to evaluate medical interventions. Unlike animal studies, clinical trials are designed to answer specific questions about how a treatment works in real people, including its safety, effectiveness, optimal dosing, and potential side effects.
Clinical trials follow a structured progression through multiple phases:
Phase I involves 20-100 participants and primarily assesses safety and dosage in healthy volunteers or patients with the target condition. These trials determine how the human body processes a treatment and identify immediate side effects.
Phase II expands to 100-300 participants with the specific health condition being targeted. Researchers evaluate whether the treatment actually works while continuing to monitor safety. This phase helps determine the most effective dose and administration schedule.
Phase III involves hundreds to thousands of participants across multiple locations. These large-scale trials provide the robust evidence needed for regulatory approval, comparing the new treatment against standard care or placebo to definitively establish effectiveness and safety.
Phase IV occurs after a treatment reaches the market, monitoring long-term effects and rare side effects in even larger populations during real-world use.
The Gap Between Animal and Human Results
Here’s where things get complicated: animal studies don’t always predict human outcomes accurately. According to a systematic review published in the BMJ, discordance between animal experiments and clinical trials occurs frequently, potentially due to bias in study design or failure of animal models to adequately mimic human disease.
The translation gap is significant. Research shows that approximately only 5% of therapies tested in animals ultimately receive regulatory approval for human use—a process that takes an average of ten years. Even more striking, about 90% of drugs that pass preclinical testing fail during human clinical trials, often due to unforeseen toxicity or lack of effectiveness.
Why the Differences Matter
Several fundamental differences between species explain these discrepancies:
Biological Variations: Humans and animals have different genetic makeups, metabolic processes, and immune responses. For example, differences in how mice respond to infection have made them poor models of sepsis, a life-threatening condition in humans. Treatments for sepsis developed in rodents have translated poorly to human patients.
Age and Health Status: Animal studies typically use young, healthy animals under controlled conditions. Human clinical trial participants, particularly those studying age-related conditions, are often older with multiple health conditions, medications, and lifestyle factors that influence outcomes.
Study Design Quality: Many animal studies lack critical design elements standard in clinical trials, such as randomization, blinding, and adequate sample sizes. These methodological shortcomings can lead to overestimated treatment effects that don’t hold up in human testing.
Outcome Measurements: Animal studies often focus on molecular mechanisms and surrogate markers, while human trials prioritize clinically meaningful outcomes that matter to patients—like quality of life, functional improvement, or disease progression.
When Animal Studies Are Valuable
Despite limitations, animal research provides crucial foundational knowledge. Animal models excel at helping scientists understand disease mechanisms, identify potential drug targets, and screen for obvious toxicity before risking human safety. They allow researchers to study interventions across an entire lifespan and examine effects on specific organs in ways impossible with human subjects.
For gut health research, animal models have helped establish how dietary compounds influence the intestinal microbiome, strengthen tight junction proteins, and promote beneficial bacteria. These mechanistic insights guide the development of targeted interventions, even though human confirmation remains essential.
The Importance of Human Validation
Given the translation gap, human clinical trials remain the gold standard for demonstrating safety and efficacy. Recent regulatory changes reflect this reality—in 2023, the FDA began allowing drug developers to use alternatives to animal testing, including computer modeling and organ-on-chip technology, before proceeding to human trials.
When evaluating health products, look for interventions backed by human clinical data, not just animal studies. A well-designed randomized controlled trial in humans provides far more confidence that a treatment will work for you than even the most promising animal results.
What This Means for Consumers
As you navigate health claims about supplements and functional ingredients, ask critical questions: Has this been tested in humans? What were the study results? How many people were involved? Were they similar to me in age and health status?
Animal studies can suggest potential benefits and mechanisms, but they’re just the starting point. Human clinical trials provide the evidence you need to make informed choices about your health. Products supported by both preclinical and clinical research offer the strongest scientific foundation.
The research on sialyllactose compounds illustrates this progression well. Initial animal studies demonstrated effects on muscle strength and gut barrier function in mice, providing mechanistic insights and safety data. However, the real validation came through human clinical trials evaluating these compounds in people with relevant health concerns. That’s why Siallac® invested in both rigorous preclinical research and human clinical studies—to ensure their Muscle Health and Gut Health formulations are backed by evidence that matters: results in real people.
References
- Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? BMJ. 2004;328(7438):514-517. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781970/
- Van Norman GA. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? JACC Basic Transl Sci. 2019;4(7):845-854. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978558/
- Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med. 2009;102(3):120-122. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746847/
- Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114-118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972460/
- FDA. Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- FDA. Step 2: Preclinical Research. https://www.fda.gov/patients/drug-development-process/step-2-preclinical-research
- Hajar R. Animal Testing and Medicine. Heart Views. 2011;12(1):42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123518/
- Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015;24(4):407-419. https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/flaws-and-human-harms-of-animal-experimentation/
- Marshall E, et al. Just 5% of therapies tested in animals end up as human drugs, new study shows. The Conversation. 2025. https://theconversation.com/just-5-of-therapies-tested-in-animals-end-up-as-as-human-drugs-new-study-shows-231920
- Mullard A. FDA no longer needs to require animal tests before human drug trials. Science. 2023. https://www.science.org/content/article/fda-no-longer-needs-require-animal-tests-human-drug-trials
- Park YE, et al. 6′-Sialyllactose Supplementation Improves Sarcopenia in Mice. Nutrients. 2024;16(16):2600. https://doi.org/10.3390/nu16162600
- Zhu Y, et al. Potential effects of sialic acid and 3′-Sialyllactose on intestinal health and anti-cardiovascular disease in mice. J Funct Foods. 2024. https://doi.org/10.1016/j.jff.2024.106215
